Cover Image
市場調查報告書

Inovio Pharmaceuticals, Inc.:開發中產品分析

Inovio Pharmaceuticals, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224584
出版日期 內容資訊 英文 73 Pages
訂單完成後即時交付
價格
Back to Top
Inovio Pharmaceuticals, Inc.:開發中產品分析 Inovio Pharmaceuticals, Inc. - Product Pipeline Review - 2016
出版日期: 2016年07月13日 內容資訊: 英文 73 Pages
簡介

Inovio Pharmaceuticals, Inc.專門從事癌症及各種染疾病的治療、預防用疫苗之開發。該公司所開發的SynCon疫苗,對既有/新菌株病原體(流感等)都顯現出高度通用性免疫反應。該公司實驗計劃中產品包含了針對白血病、C型肝炎、子宮頸再生不良用的PhaseⅡ實驗,以及HIV·流感的PhaseⅠ臨床實驗等產品。

本報告提供美國的生物醫藥品企業──Inovio Pharmaceuticals, Inc.(Inovio)的醫藥品研究開發進展相關分析,提供該公司的產品平台結構,及臨床實驗的整體進展,主要開發中產品的簡介與開發情形,以及該公司簡介及最新趨勢等調查。

目錄

Inovio Pharmaceuticals, Inc.:現狀

  • 企業概要
  • 主要資訊
  • 主要資料

研究開發(R&D)概況

  • 主要的治療領域

開發平台·檢討

  • 各開發階段的開發中產品
  • 開發中產品:單劑治療藥
  • 開發中產品:並用治療模式
  • 開發中產品:合作夥伴產品
    • 合作夥伴產品/並用治療模式
  • 開發中產品:合作產品
    • 合作產品/並用治療模式

開發中產品的概要

  • 臨床實驗階段的開發中產品
    • PhaseⅡ產品/並用治療模式
    • PhaseⅠ產品/並用治療模式
  • 初期階段的開發中產品
    • 臨床實驗前產品/並用治療模式

藥物簡介

  • VGX-3100
    • 產品概要
    • 作用機制
    • 研究開發(R&D)的發展
  • Syncon H1N1流感通用·疫苗
  • INO-3112
  • INO-3401
  • INO-3510
  • INO-3605
  • INO-3609
  • INO-8000
  • PENNVAX-B
  • Pennvax-G
  • VGX-1027
  • VGX-3400X
  • VRC-01
  • DNA Vaccine for Chikungunya
  • H3N2流感DNA疫苗
  • H7N9流感通用DNA疫苗
  • MERS犬冠狀病毒感染疾病DNA疫苗
  • 天花DNA疫苗
  • DNAbase IL-33+人類乳突病毒(HPV)-16 DNA疫苗
  • INO-1400
  • INO-7103
  • INO-7105
  • MAV-12
  • Pennvax-GP
  • Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses

開發平台分析

  • 標的別
  • 各投藥法
  • 分子類別
  • 各作用機制

開發中產品的最新趨勢

暫停開發的產品

中止開發的產品

  • 中止開發的產品簡介
    • mifepurisuton
    • VGX-410C

企業的聲明

公司所在地及子公司

  • 總公司
  • 其他的公司所在地·子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08087CDB

Summary

Global Markets Direct's, 'Inovio Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the Inovio Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Inovio Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Inovio Pharmaceuticals, Inc.
  • The report provides overview of Inovio Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Inovio Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Inovio Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Inovio Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Inovio Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Inovio Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Inovio Pharmaceuticals, Inc. Snapshot
    • Inovio Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Inovio Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Inovio Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Inovio Pharmaceuticals, Inc. - Pipeline Products Glance
    • Inovio Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Inovio Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Inovio Pharmaceuticals, Inc. - Drug Profiles
    • VGX-3100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INO-8000
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FVH-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strain A/H3N2] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INO-1400
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INO-3106
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INO-3510
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INO-4212
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INO-4500
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INO-5150
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PENNVAX-B
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PENNVAX-G
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PENNVAX-GP
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VGX-3400X
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VRC-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • chikungunya vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Clostridium difficile vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Ebola Virus Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INO-5400
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAV-12
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Tyrosinase for Oncology and Immunology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Chikungunya
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • respiratory syncytial virus vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RSQ-15
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccines for Neurological Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Inovio Pharmaceuticals, Inc. - Pipeline Analysis
    • Inovio Pharmaceuticals, Inc. - Pipeline Products by Target
    • Inovio Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Inovio Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Inovio Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Inovio Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Inovio Pharmaceuticals, Inc. - Dormant Projects
  • Inovio Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • mifepristone
      • VGX-410C
  • Inovio Pharmaceuticals, Inc. - Company Statement
  • Inovio Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Inovio Pharmaceuticals, Inc., Key Information
  • Inovio Pharmaceuticals, Inc., Key Facts
  • Inovio Pharmaceuticals, Inc. - Pipeline by Indication, 2016
  • Inovio Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Inovio Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Inovio Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016
  • Inovio Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Inovio Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2016
  • Inovio Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Inovio Pharmaceuticals, Inc. - Phase II, 2016
  • Inovio Pharmaceuticals, Inc. - Phase I, 2016
  • Inovio Pharmaceuticals, Inc. - Preclinical, 2016
  • Inovio Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • Inovio Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Inovio Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Inovio Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Inovio Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
  • Inovio Pharmaceuticals, Inc. - Dormant Developmental Projects,2016
  • Inovio Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016
  • Inovio Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Inovio Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
  • Inovio Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Inovio Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Inovio Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016
  • Inovio Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Inovio Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Inovio Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
Back to Top